Compare MUJ & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUJ | ORGO |
|---|---|---|
| Founded | 1998 | 1985 |
| Country | United States | United States |
| Employees | N/A | 869 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.8M | 732.3M |
| IPO Year | N/A | N/A |
| Metric | MUJ | ORGO |
|---|---|---|
| Price | $12.13 | $5.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 108.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $465,218,000.00 |
| Revenue This Year | N/A | $8.14 |
| Revenue Next Year | N/A | $6.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.24 |
| 52 Week Low | $9.74 | $2.61 |
| 52 Week High | $11.70 | $7.08 |
| Indicator | MUJ | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 60.57 |
| Support Level | $11.96 | $4.66 |
| Resistance Level | $12.09 | $5.80 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 82.86 | 80.63 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.